Debiopharm Group

Debiopharm, Ascenta ink exclusive license agreement

Wednesday, September 7, 2011 11:11 AM

Debiopharm Group and Ascenta Therapeutics have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.

More... »


INC Research forms partnership with Debiopharm Group

Wednesday, July 27, 2011 01:25 PM

INC Research, a therapeutically focused CRO, and Debiopharm Group, a Swiss-based global biopharmaceutical group, have formed a strategic partnership.

More... »


Debiopharm names management team

Wednesday, July 20, 2011 11:32 AM

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies, has named a number of management figures to key positions.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs